We intend to bring our products to market using the following business strategies:

• Develop Gut-Targeted Therapeutics for Significant Unmet Medical Needs
  By focusing our proprietary oral antibody platform on serious diseases that can be treated locally via the gastrointestinal tract, we believe we can create important new therapeutic products within a unique and defensible market space.
• Implement a Flexible, Capital-Efficient Plan Using a Semi-Virtual Business Model
  Around a small team of experienced management, we have built a lean organization that leverages CRO's to meet our research goals. This approach enables us to harness a wide range of capabilities while keeping our overhead and fixed expenses very low.
• Advance Products Through Early Clinical Trials
  We believe we can achieve compelling returns for our investors by demonstrating the breadth and value of our technology platform and products in preclinical research and early clinical trials (up to Phase 2).